期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 52, 期 -, 页码 173-179出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejps.2013.11.012
关键词
Inflammatory bowel diseases; Fatty acid amide hydrolase; Endogenous cannabinoid system; Abdominal pain
资金
- Iuventus Plus program of the Polish Ministry of Science and Higher Education [0119/IP1/2011/71, 0107/IP1/2013/72]
- Medical University of Lodz
Fatty acid amide hydrolase (FAAH) is the enzyme crucially inVolved in the modulation of physiological processes mediated by anandamide (AEA), as well as other endocannabinoids and non-cannabinoid biolipids in the gastrointestinal (GI) tract. FAAH also plays a major role in the etiology and the course of GI diseases and the inhibition of the enzyme has recently become a potential target for their therapy. In this review we look at the pharmacology of FAAH and possible clinical application of FAAH inhibitors in the treatment of GI disorders. In particular, we focus on inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), whose symptoms include abdominal pain and motility disturbances. We also discuss why the inhibitor-based drugs may replace in future conventional therapies for IBD and IBS. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据